ENSCW (Ensysce Biosciences) Float Percentage Of Total Shares Outstanding: N/A (As of Jun. 28, 2026)


ENSCW Ensysce Biosciences Inc ENSCW
23 GF Score
Price $0.00
! 2 Warning Signs
View Full Analysis

What is Ensysce Biosciences Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Ensysce Biosciences's float shares is 0.00 Mil. Ensysce Biosciences's total shares outstanding is 0.00 Mil. Ensysce Biosciences's float percentage of total shares outstanding is N/A.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Ensysce Biosciences's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Ensysce Biosciences's Institutional Ownership is 0.00%.

ENSCW
23GF Score
Ensysce Biosciences Inc ENSCW
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ensysce Biosciences Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Ensysce Biosciences's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=0.00/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ensysce Biosciences Business Description

Other Exchanges ENSC:USA
Address 7946 Ivanhoe Avenue, Suite 201, La Jolla, CA, USA, 92037
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
23GF Score

Get the complete analysis for ENSCW

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price